borofalan (10B)

Drug profile

Key facts

borofalan (10B) is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2020. DrugCentral lists 1 molecular target, including Slc7a5. Recorded indications include Neoplasm of head and neck.

• Molecular targets: Slc7a5 (1 listed in DrugCentral).
• Indications: Neoplasm of head and neck.
• Molecular formula: C9H12BNO4; molecular weight 208.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Neoplasm of head and neck

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
L-type amino acid transporter 1	Slc7a5	substrate	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2020-03-25	PMDA	—	Stella Pharma

Chemical structure

• Molecular formula: C₉H₁₂BNO₄
• Molecular weight: 208.21 g/mol
• CAS number: 80994-59-8
• InChIKey: NFIVJOSXJDORSP-UHFFFAOYSA-N
• PubChem CID: 25033700

B(C1=CC=C(C=C1)CC(C(=O)O)N)(O)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is borofalan (10B) used for?

DrugCentral lists the following indications for borofalan (10B): Neoplasm of head and neck.

How does borofalan (10B) work?

Its molecular targets in DrugCentral include Slc7a5 (substrate).

When was borofalan (10B) first approved?

borofalan (10B) was first approved by the PMDA in 2020.

What is the chemical formula of borofalan (10B)?

borofalan (10B) has the molecular formula C9H12BNO4 and a molecular weight of 208.21 g/mol.

Sources

• DrugCentral drug card 5422 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• PubChem CID 25033700 — chemical identifiers
• FDA UNII 57659839UA — substance identity

How this page is built: methodology · editorial policy & corrections.